In light of the new ruling, patent licensees may want to re-evaluate the strength of their licensed patents.
Michael A. Gollin
Advertisement
Articles by Michael A. Gollin
Advertisement
Latest Updated Articles
Myriad Decision Places Biotech at a CrossroadsPublished: August 1st 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
